Latest Conference Articles

August 2nd 2021, 8:29pm

International Congress on the Future of Breast Cancer West

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

August 2nd 2021, 8:24pm

International Congress on the Future of Breast Cancer West

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

August 1st 2021, 3:46pm

International Lung Cancer Congress

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

August 1st 2021, 3:44pm

International Lung Cancer Congress

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

August 1st 2021, 3:33pm

International Lung Cancer Congress

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

July 31st 2021, 6:00pm

International Lung Cancer Congress

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

July 31st 2021, 5:26pm

International Lung Cancer Congress

Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

July 31st 2021, 2:00pm

International Lung Cancer Congress

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

July 31st 2021, 1:00pm

International Lung Cancer Congress

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

July 31st 2021, 1:00pm

International Lung Cancer Congress

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

July 31st 2021, 12:00pm

International Lung Cancer Congress

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

July 30th 2021, 10:16pm

International Congress on the Future of Breast Cancer West

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

July 30th 2021, 9:38pm

International Lung Cancer Congress

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

July 30th 2021, 7:57pm

International Lung Cancer Congress

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

July 30th 2021, 6:40pm

International Lung Cancer Congress

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

July 30th 2021, 6:30pm

International Lung Cancer Congress

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

July 30th 2021, 5:13pm

International Lung Cancer Congress

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

July 29th 2021, 9:41pm

International Lung Cancer Congress

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

July 29th 2021, 9:00pm

International Lung Cancer Congress

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

July 27th 2021, 5:00pm

ASCO Direct Highlights

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.